Is A Aurora Cannabis Inc. (ACB) Big Rally On The Horizon?

Aurora Cannabis Inc. (ACB) will probably climb -100 percent over the next 12 months, according to price target estimates compiled by finviz.

Aurora Cannabis Inc. (ACB) will probably climb -100 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $15price as 12-month high target. This represents a whopping 132.92 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $10.75, which represents a return potential of 66.93 percent when compared to the closing price of the stock of $6.44 on Friday, January 18. The lowest price target for the stock is $6 — slightly more than -6.83 percent from ACB’s current share price.

The stock is currently hovering around the first support level of $6.15. Below this, the next support is placed in the zone of $5.85. Till the time, the ACB stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 56.59 on daily chart, which may remain a cause for concern. If the price breaks below $5.85 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $6.79 mark may result into a pull-back move towards $7.13 level.

On 18th of January, Aurora Cannabis Inc. (NYSE:ACB) shares ended lower after a volatile session. The shares dropped -0.13 points or -1.98 percent at $6.44 with a heavy trade volume of 39.208 million shares. After opening the session at $6.68, the shares went as high as $6.84 and as low as $6.2, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $6.22 billion and now has 965.11 million shares outstanding. Aurora Cannabis Inc. (ACB) stock has gained 16.46 percent of market value in 21 trading days.

ACB stock has a trailing 3-year beta of 0, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was $0.22 a share in the trailing twelve months. The stock’s value has surged 29.84 percent year to date (YTD) against a decline of -36.15 percent in 12 month’s time. The company’s shares still trade -48.58 percent away from its 1-year high of $12.52 and 65.13 percent up from 52-week low of $3.90. The average consensus rating on the company is 0, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.

Shares of Aurora Cannabis Inc. (ACB) are trading at a P/E ratio of 30.91 times earnings reported for the past 12 months. The industry ACB operates in has an average P/E of 29.45. Its P/E ratio went as low as 58.71X and as high as 58.71 over the 5-year span. Further, it is sporting a 107.91 on the Price-to-Sales ratio. Compare this with the industry average P/S of 19.89. 0 percent is the gross profit margin for Aurora Cannabis Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

Let’s take a look at some insider activity at Aurora Cannabis Inc. (NYSE:ACB) and see the pattern.

Related Posts:

  • No Related Posts

Reviewing Endo International plc (ENDP)’s and Aurora Cannabis Inc. (NYSE:ACB)’s results.

As Drug Manufacturers – Other companies, Endo International plc (NASDAQ:ENDP) and Aurora Cannabis Inc. (NYSE:ACB) are our subject to contrast …

As Drug Manufacturers – Other companies, Endo International plc (NASDAQ:ENDP) and Aurora Cannabis Inc. (NYSE:ACB) are our subject to contrast. And more specifically their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Endo International plc 2.93B 0.74 967.87M -4.49 0.00
Aurora Cannabis Inc. N/A 0.00 N/A 0.22 26.53

We can see in table 1 the earnings per share, top-line revenue and valuation of Endo International plc and Aurora Cannabis Inc..

Profitability

Table 2 has Endo International plc and Aurora Cannabis Inc.’s net margins, return on equity (ROE) and return on assets.

Net Margins Return on Equity Return on Assets
Endo International plc -33.03% 0% -10.1%
Aurora Cannabis Inc. 0.00% 0% 0%

Analyst Recommendations

In next table is delivered Endo International plc and Aurora Cannabis Inc.’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Endo International plc 0 6 4 2.40
Aurora Cannabis Inc. 0 0 0 0.00

The average price target of Endo International plc is $16.89, with potential upside of 74.12%.

Institutional and Insider Ownership

Endo International plc and Aurora Cannabis Inc. has shares held by institutional investors as follows: 0% and 5.77%. Endo International plc’s share held by insiders are 0.7%. Comparatively, Aurora Cannabis Inc. has 3.09% of it’s share held by insiders.

Summary

On 5 of the 9 factors Aurora Cannabis Inc. beats Endo International plc.

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. The companyÂ’s U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. The company has operations in 19 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

As of February, 14 The EPS for Aurora Cannabis Inc. (ACB) Expected At $-0.04

Aurora Cannabis Inc. (TSE:ACB)’s earnings release is awaited by WallStreet on February, 14, as reported by RTT. Last year’s EPS was $0.02, while …

Aurora Cannabis Inc. (TSE:ACB)’s earnings release is awaited by WallStreet on February, 14, as reported by RTT. Last year’s EPS was $0.02, while now analysts expect change of 300.00 % down from current $-0.04 EPS. After $0.12 EPS report last quarter, Wall Street now predicts -133.33 % negative EPS growth of Aurora Cannabis Inc.. The stock decreased 1.52% or $0.13 during the last trading session, hitting $8.4.Aurora Cannabis Inc. has volume of 7.49 million shares. Since January 22, 2018 ACB has 0.00% and is . The stock the S&P500 by 0.00%.

Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada.The company has $8.38 billion market cap. The company’s products consist of dried cannabis and cannabis oil.The P/E ratio is 29.27. It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union; and produces and sells proprietary systems for the indoor cultivation of cannabis, organic microgreens, vegetables, and herbs.

For more Aurora Cannabis Inc. (TSE:ACB) news published briefly go to: Midasletter.com, Forbes.com, Finance.Yahoo.com, Profitconfidential.com or Midasletter.com. The titles are as follows: “WATCH: Aurora Cannabis Inc (TSE:ACB) CCO Cam Battley on the Master Plan – Midas Letter” published on July 23, 2018, “What’s Ahead For Aurora Cannabis After An Impressive FY 2018 – Forbes” on September 26, 2018, “Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week – Yahoo! Finance News” with a publish date: January 21, 2019, “Aurora Stock Forecast 2019: 3 Catalysts That Could Attract U.S. Investors Post NYSE:ACB Listing – Profit Confidential” and the last “Aurora Cannabis Inc (TSE:ACB | NYSE:ACB) “Highest Revenue Industry Has Ever Seen” – Midas Letter” with publication date: November 23, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

As of February, 14 Analysts See $-0.04 EPS for Aurora Cannabis Inc. (ACB)

Aurora Cannabis Inc. (TSE:ACB)’s quarterly earnings will be revealed on February, 14., RTT reports. Analysts forecast 300.00 % diference or $-0.04 …

Aurora Cannabis Inc. (TSE:ACB)’s quarterly earnings will be revealed on February, 14., RTT reports. Analysts forecast 300.00 % diference or $-0.04 from the $0.02 EPS from 2018. Analysts at Wall Street see Aurora Cannabis Inc.’s -133.33 % negative EPS growth compared to $0.12 EPS for previous quarter. ACB is reaching $8.4 during the last trading session, after decreased 1.52%.Currently Aurora Cannabis Inc. is after 0.00% change in last January 22, 2018. ACB has also 7.49 million shares volume. The stock the S&P500 by 0.00%.

Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada.The firm is worth $8.38 billion. The company’s products consist of dried cannabis and cannabis oil.The P/E ratio is 29.27. It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union; and produces and sells proprietary systems for the indoor cultivation of cannabis, organic microgreens, vegetables, and herbs.

For more Aurora Cannabis Inc. (TSE:ACB) news brought out recently go to: Midasletter.com, Stockhouse.com, Investorplace.com, Midasletter.com or Midasletter.com. The titles are as follows: “Canopy Growth Corp (TSE:WEED) Surge: Benjamin A. Smith Called This Market Move – Midas Letter” brought out on January 15, 2019, “Generating Cash Flow from Cannabis Waste-C.MWM-T.ACB-P.CANNABIS – Stockhouse” on January 17, 2019, “3 Strikes Against Aurora Stock and Why You Can Ignore Them – Investorplace.com” with a publish date: December 31, 2018, “VIDEO: Campaign for Cannabis Amnesty on Aurora Cannabis Inc (TSE:ACB) Support – Midas Letter” and the last “Aurora Cannabis Inc (TSE:ACB) Strategic Wager: Dilute Now To Establish Strategic Preeminence – Midas Letter” with publication date: May 14, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aurora Cannabis Inc (ACB) Shares Bought by QCI Asset Management Inc. NY

QCI Asset Management Inc. NY raised its holdings in Aurora Cannabis Inc (NYSE:ACB) by 4.8% during the fourth quarter, according to the company in …

Aurora Cannabis logoQCI Asset Management Inc. NY raised its holdings in Aurora Cannabis Inc (NYSE:ACB) by 4.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 86,159 shares of the company’s stock after purchasing an additional 3,913 shares during the quarter. QCI Asset Management Inc. NY’s holdings in Aurora Cannabis were worth $427,000 as of its most recent SEC filing.

Separately, Griffin Asset Management Inc. acquired a new stake in shares of Aurora Cannabis during the 3rd quarter valued at $128,000. Institutional investors own 0.02% of the company’s stock.

Shares of NYSE ACB traded down $0.13 during mid-day trading on Monday, hitting $6.44. 39,328,637 shares of the stock traded hands, compared to its average volume of 17,815,378. The company has a quick ratio of 5.68, a current ratio of 6.54 and a debt-to-equity ratio of 0.07. Aurora Cannabis Inc has a twelve month low of $4.05 and a twelve month high of $12.52. The company has a market cap of $6.43 billion and a price-to-earnings ratio of 33.90.

Aurora Cannabis (NYSE:ACB) last released its quarterly earnings data on Monday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.13. Aurora Cannabis had a return on equity of 8.57% and a net margin of 224.33%. The company had revenue of $22.71 million for the quarter.

COPYRIGHT VIOLATION NOTICE: “Aurora Cannabis Inc (ACB) Shares Bought by QCI Asset Management Inc. NY” was first posted by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/21/qci-asset-management-inc-ny-acquires-3913-shares-of-aurora-cannabis-inc-acb.html.

Aurora Cannabis Company Profile

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Story: How is the S&P 500 index different from the DJIA?

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts